Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient with graft-versus-host disease

被引：0

作者：

Kuhnowski F. ^{[1
]}

Terriou L. ^{[1
]}

Magro L. ^{[1
]}

Jouet J.-P. ^{[1
]}

Yakoub-Agha I. ^{[1
]}

机构：

[1] Service des Maladies du Sang, UAM Allogreffes de CSH, CHRU, Lille

来源：

Drugs | 2006年 / 66卷 / Suppl 2期

关键词：

Imatinib; Tacrolimus; Chronic Myeloid Leukaemia; Mycophenolate Mofetil; Busulfan;

D O I：

10.2165/00003495-200666002-00009

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：29 / 31

页数：2

共 50 条

[1] Resolution of gastrointestinal side effects in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)
Tuncer M.
Drugs, 2006, 66 (Suppl 2) : 9 - 10
[2] Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) resolves gastrointestinal disorders in a patient with severe idiopathic aplastic anaemia
Rohrlich P.-S.
Deconinck E.
Cahn J.-Y.
Plouvier E.
Drugs, 2006, 66 (Suppl 2) : 33 - 35
[3] Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) in Patients with Gastrointestinal Side Effects: Case Studies
Anita Boswell
Magdi Shehata
Drugs, 2006, 66 (Suppl 2) : 19 - 22
[4] Resolution of severe diarrhoea and return to work in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)
Lord H.
Drugs, 2006, 66 (Suppl 2) : 11 - 13
[5] Complete Resolution of Severe Diarrhoea after Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) in a Patient at High Immunological Risk
Thomas Breidenbach
Marcus Spangenberg
Eckhard Nagel
Drugs, 2006, 66 (Suppl 2) : 25 - 27
[6] Improvement in Social Functioning in Kidney Transplant Patients after Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®): Three Case Studies
Tariq Shah
Drugs, 2006, 66 (Suppl 2) : 15 - 17
[7] Resolution of severe anaemia and hypotension secondary to rectal ulcers in a renal transplant patient after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)
Ortega F.
Baltar J.
Drugs, 2006, 66 (Suppl 2) : 23 - 24
[8] Gastrointestinal Quality of Life Improvement of Renal Transplant Recipients Converted From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Drugs or Agents: Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium
Ortega, Francisco
Sanchez-Fructuoso, Ana
Maria Cruzado, Jose
Carlos Gomez-Alamillo, Juan
Alarcon, Antonio
Pallardo, Lluis
Maria Morales, Jose
Oliver, Juan
Guinea, Guillermo
TRANSPLANTATION, 2011, 92 (04) : 426 - 432
[9] Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function
Meneses, Rejane de Paula
Kotsifas, Cecilia Halusch
PEDIATRIC TRANSPLANTATION, 2009, 13 (02) : 188 - 193
[10] Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease
Jones, Rachel B.
Walsh, Michael
Chaudhry, Afzal N.
Smith, Kenneth G. C.
Jayne, David R. W.
CLINICAL KIDNEY JOURNAL, 2014, 7 (06): : 562 - 568

← 1 2 3 4 5 →